Literature DB >> 28114225

Subcutaneous Lobular Capillary Hemangioma on 68Ga-PSMA PET/CT.

Mads Ryø Jochumsen1, Mikkel Holm Vendelbo, Søren Høyer, Kirsten Bouchelouche.   

Abstract

We present a case of a subcutaneous process in the abdominal wall with high prostate-specific membrane antigen (PSMA) activity on Ga-PSMA PET/CT. Histology demonstrated a benign lobular capillary hemangioma with a high vascular density, with highly PSMA-positive endothelial cells. It is well known that PSMA is expressed in different tissue, including neovasculature in various malignant tumors, and the knowledge is rapidly evolving as new discoveries appear.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28114225     DOI： 10.1097/RLU.0000000000001542

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


  8 in total

1.  [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.

Authors:  Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-12-15

2.  68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients.

Authors:  Paola Caroli; Israel Sandler; Federica Matteucci; Ugo De Giorgi; Licia Uccelli; Monica Celli; Flavia Foca; Domenico Barone; Antonino Romeo; Anna Sarnelli; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-19       Impact factor: 9.236

Review 3.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

Review 4.  Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors:  Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-01       Impact factor: 9.236

5.  18F DCFPyL PSMA avid biopsy proven subcutaneous capillary haemangioma as a malignancy mimic in the setting of biochemical recurrent prostate carcinoma.

Authors:  Manvinder Dhillon; Dalveer Singh
Journal:  Radiol Case Rep       Date:  2022-04-19

6.  Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis.

Authors:  Thomas J W Klein Nulent; Robert J J van Es; Gerard C Krijger; Remco de Bree; Stefan M Willems; Bart de Keizer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-07       Impact factor: 9.236

7.  Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.

Authors:  Ali Afshar-Oromieh; Tim Holland-Letz; Frederik L Giesel; Clemens Kratochwil; Walter Mier; Sabine Haufe; Nils Debus; Matthias Eder; Michael Eisenhut; Martin Schäfer; Oliver Neels; Markus Hohenfellner; Klaus Kopka; Hans-Ulrich Kauczor; Jürgen Debus; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-12       Impact factor: 9.236

Review 8.  Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings.

Authors:  Felipe de Galiza Barbosa; Marcelo Araujo Queiroz; Rafael Fernandes Nunes; Larissa Bastos Costa; Elaine Caroline Zaniboni; José Flavio Gomes Marin; Giovanni Guido Cerri; Carlos Alberto Buchpiguel
Journal:  Cancer Imaging       Date:  2020-03-14       Impact factor: 3.909
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.